title: Campylobacter concisus: a new character in the Crohn's disease story?
authors.forename: Mario
authors.initials: M
authors.lastname: Guslandi
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Si Ming
authors.initials: SM
authors.lastname: Man
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Day
authors.forename: Steven T
authors.initials: ST
authors.lastname: Leach
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Lemberg
authors.forename: Shoma
authors.initials: S
authors.lastname: Dutt
authors.forename: Michael
authors.initials: M
authors.lastname: Stormon
authors.forename: Anthony
authors.initials: A
authors.lastname: Otley
authors.forename: Edward V
authors.initials: EV
authors.lastname: O'Loughlin
authors.forename: Annabel
authors.initials: A
authors.lastname: Magoffin
authors.forename: Patrick H Y
authors.initials: PH
authors.lastname: Ng
authors.forename: Hazel
authors.initials: H
authors.lastname: Mitchell
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002167:Campylobacter / Q000302:isolation & purification*; D002169:Campylobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology*; D002648:Child; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology*; D006801:Humans; D012294:Rifamycins / Q000627:therapeutic use*; D000078262:Rifaximin
chemical_list: D000900:Anti-Bacterial Agents; D012294:Rifamycins; D000078262:Rifaximin